Does Rallies show Form 4 insider transactions for GNPX?

Yes. Rallies tracks GNPX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is GNPX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for GNPX. It does not provide personalized investment advice.

GNPX (Genprex, Inc. Common Stock) Stock Analysis - Insider Trades

Genprex, Inc. Common Stock (GNPX) is a publicly traded Healthcare sector company. As of May 20, 2026, GNPX trades at $0.79 with a market cap of $8.39M and a P/E ratio of -0.04. GNPX moved -1.47% today. Year to date, GNPX is -56.12%; over the trailing twelve months it is -94.52%. Its 52-week range spans $0.74 to $198.50. Rallies surfaces GNPX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading GNPX stock inside the company?

Recent GNPX insider activity includes LONGNECKER BRENT M sold 8, LONGNECKER BRENT M sold 10, Varner John Rodney bought 19.00K, VACZY CATHERINE M bought 20.00K, and LONGNECKER BRENT M bought 15.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

GNPX Key Metrics

Key financial metrics for GNPX
Metric	Value
Price	$0.79
Market Cap	$8.39M
P/E Ratio	-0.04
EPS	$-17.40
Dividend Yield	0.00%
52-Week High	$198.50
52-Week Low	$0.74
Volume	211.51K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-16.23M
Gross Margin	0.00%

Recent GNPX Insider Trades

LONGNECKER BRENT M sold 8 (~$9.84) on Apr 14, 2026.
LONGNECKER BRENT M sold 10 (~$12.3) on Apr 14, 2026.
Varner John Rodney bought 19.00K (~$20.05K) on Apr 21, 2023.
VACZY CATHERINE M bought 20.00K (~$21.48K) on Apr 21, 2023.
LONGNECKER BRENT M bought 15.00K (~$62.25K) on Apr 5, 2021.

Latest GNPX News

Genprex Partners with MD Anderson to Study TROP2, PTEN Biomarkers for Reqorsa Trials — Apr 21, 2026
Genprex Preclinical Data Show 79% Tumor Shrinkage and Biomarker Insight for Lung Cancer — Apr 20, 2026
Genprex Stock Drops 9.5% After Congressman Moore Buys $1,000–$15,000 Stake — Feb 26, 2026
Genprex Secures Japanese, European Patents for REQORSA-Immunotherapy Combinations — Feb 23, 2026

GNPX Analyst Consensus

GNPX analyst coverage data. Average price target: $0.00.

Common questions about GNPX

Who is trading GNPX stock inside the company?: Recent GNPX insider activity includes LONGNECKER BRENT M sold 8, LONGNECKER BRENT M sold 10, Varner John Rodney bought 19.00K, VACZY CATHERINE M bought 20.00K, and LONGNECKER BRENT M bought 15.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for GNPX?: Yes. Rallies tracks GNPX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is GNPX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for GNPX. It does not provide personalized investment advice.